CryoLife gets $99,000 research grant:
This article was originally published in Clinica
CryoLife (US) has been awarded a $99,000 Phase I innovative research grant from the US NIH for its bioengineered human implantable heart valve. CryoLife will conduct studies using a porcine heart valve collagen matrix that can be "seeded" with human cells with the goal of creating a non-immunogenic heart valve for application in human replacement surgery. CryoLife has received four previous NIH grants since 1991, totalling $284,000 in development funding.
You may also be interested in...
Biopharma was an attractive investment in 2020 and fundamentals are unchanged in 2021, including the pandemic’s work-at-home requirements, which allowed more companies to go public faster.
Abbott reported almost 28% revenue growth in the fourth quarter led by the exploding demand for COVID-19 tests and continued success of its FreeStyle Libre continuous glucose monitor.
While representing a smaller population, the ACTIVATE-T trial targeted patients seen as having greater unmet need.